CN100572376C - 用作tafia抑制剂的咪唑衍生物 - Google Patents

用作tafia抑制剂的咪唑衍生物 Download PDF

Info

Publication number
CN100572376C
CN100572376C CNB2005800115593A CN200580011559A CN100572376C CN 100572376 C CN100572376 C CN 100572376C CN B2005800115593 A CNB2005800115593 A CN B2005800115593A CN 200580011559 A CN200580011559 A CN 200580011559A CN 100572376 C CN100572376 C CN 100572376C
Authority
CN
China
Prior art keywords
alkyl
imidazol
independently
twice
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2005800115593A
Other languages
English (en)
Chinese (zh)
Other versions
CN1950357A (zh
Inventor
C·卡鲁斯
H·海奇
A·林登施密德
S·格吕内贝格
H·西莱特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34964308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100572376(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of CN1950357A publication Critical patent/CN1950357A/zh
Application granted granted Critical
Publication of CN100572376C publication Critical patent/CN100572376C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNB2005800115593A 2004-04-22 2005-04-07 用作tafia抑制剂的咪唑衍生物 Expired - Fee Related CN100572376C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004020186.2 2004-04-22
DE102004020186A DE102004020186A1 (de) 2004-04-22 2004-04-22 Heterocyclylessigsäuren als Inhibitoren von TAFla

Publications (2)

Publication Number Publication Date
CN1950357A CN1950357A (zh) 2007-04-18
CN100572376C true CN100572376C (zh) 2009-12-23

Family

ID=34964308

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2005800115593A Expired - Fee Related CN100572376C (zh) 2004-04-22 2005-04-07 用作tafia抑制剂的咪唑衍生物

Country Status (34)

Country Link
EP (2) EP1864979B1 (https=)
JP (1) JP4939401B2 (https=)
KR (1) KR101162047B1 (https=)
CN (1) CN100572376C (https=)
AR (1) AR053302A1 (https=)
AT (2) ATE386737T1 (https=)
AU (1) AU2005238144B2 (https=)
BR (1) BRPI0510159A (https=)
CA (1) CA2563401C (https=)
CR (1) CR8650A (https=)
CY (1) CY1108087T1 (https=)
DE (2) DE102004020186A1 (https=)
DK (1) DK1740569T3 (https=)
EC (1) ECSP066941A (https=)
ES (1) ES2299026T3 (https=)
HR (1) HRP20080099T3 (https=)
IL (1) IL178672A (https=)
MA (1) MA28543B1 (https=)
MY (1) MY140903A (https=)
NI (1) NI200600217A (https=)
NO (1) NO20065320L (https=)
NZ (1) NZ550757A (https=)
PE (1) PE20060172A1 (https=)
PL (1) PL1740569T3 (https=)
PT (1) PT1740569E (https=)
RS (1) RS50553B (https=)
RU (1) RU2375356C2 (https=)
SI (1) SI1740569T1 (https=)
TN (1) TNSN06341A1 (https=)
TW (1) TWI359016B (https=)
UA (1) UA87306C2 (https=)
UY (1) UY28868A1 (https=)
WO (1) WO2005105781A1 (https=)
ZA (1) ZA200607668B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102884053A (zh) * 2010-03-18 2013-01-16 第一三共株式会社 环丙烷甲酸衍生物

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150514T1 (hr) 2006-12-06 2015-09-11 Sanofi DERIVATI SULFAMIDA KAO INHIBITORI TAFIa
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
MX2009008777A (es) * 2007-02-13 2009-08-25 Schering Corp Derivados y analogos de cromano como agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos.
AU2008279447A1 (en) * 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
WO2009103432A2 (en) * 2008-02-21 2009-08-27 Sanofi-Aventis Covalently binding imaging probes
SI2300462T1 (sl) 2008-06-06 2014-09-30 Sanofi Makrociklični sečninski in sulfamidni derivati kot inhibitorji za TAFIa
NZ592764A (en) 2008-10-29 2012-08-31 Taisho Pharmaceutical Co Ltd Compound having tafia inhibitory activity
KR20120016651A (ko) * 2009-05-15 2012-02-24 사노피 Ｔａｆｉａ의 억제제로서 유용한 화합물의 제조방법
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US8410127B2 (en) 2009-10-01 2013-04-02 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
DK2548871T3 (da) 2010-03-18 2017-11-06 Daiichi Sankyo Co Ltd Cycloalkylsubstitueret imidazolderivat
MX2013004193A (es) * 2010-11-11 2013-06-05 Sanofi Sa Procedimiento para la preparacion de derivados de acido 3-(6-amino-piridin-3-il)-2-acrilico.
EP2782576B1 (en) 2011-11-25 2016-05-18 Sanofi Sodium salt of (r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
EP2782574B1 (de) 2011-11-25 2016-03-30 Sanofi Salz von (r)-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1h-imidazol-4-yl)- propionsäureethylester
EP2782575B1 (en) 2011-11-25 2016-04-20 Sanofi Crystalline salts of r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
CA2914533A1 (en) 2013-06-10 2014-12-18 Sanofi Macrocyclic urea derivatives as inhibitors of tafia, their preparation and their use as pharmaceuticals
EP3437641A4 (en) 2016-03-29 2019-11-20 Daiichi Sankyo Company, Limited THERAPEUTIC AGENT AGAINST INFLAMMATORY DARMER DISEASE
AU2017305392A1 (en) 2016-08-03 2019-02-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003013526A1 (en) * 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0104657A3 (en) * 1998-12-24 2002-07-29 Astellas Pharma Inc Chuo Ku Imidazole compounds and pharmaceutical compositions containing them
WO2003061653A1 (en) 2002-01-22 2003-07-31 Pfizer Limited 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003013526A1 (en) * 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Imidazole acetic acid TAFIa inhibitors: SAR studies centeredaround the basic P' group. Philippe G.Nantermet等.Bioorganic & medicinal chemistry letters,Vol.14. 2004 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102884053A (zh) * 2010-03-18 2013-01-16 第一三共株式会社 环丙烷甲酸衍生物
US8946443B2 (en) 2010-03-18 2015-02-03 Daiichi Sankyo Company, Limited Cyclopropanecarboxylic acid derivative
CN102884053B (zh) * 2010-03-18 2016-03-02 第一三共株式会社 环丙烷甲酸衍生物
US9662310B2 (en) 2010-03-18 2017-05-30 Daiichi Sankyo Company, Limited Cyclopropanecarboxylic acid derivative

Also Published As

Publication number Publication date
KR101162047B1 (ko) 2012-07-04
JP2007533672A (ja) 2007-11-22
TW200602325A (en) 2006-01-16
HRP20080099T3 (en) 2008-03-31
DK1740569T3 (da) 2008-06-02
TNSN06341A1 (en) 2008-02-22
MA28543B1 (fr) 2007-04-03
CN1950357A (zh) 2007-04-18
BRPI0510159A (pt) 2007-10-02
PL1740569T3 (pl) 2008-07-31
NI200600217A (es) 2008-06-17
RU2006141246A (ru) 2008-06-10
NO20065320L (no) 2007-01-12
CY1108087T1 (el) 2014-02-12
ATE523505T1 (de) 2011-09-15
IL178672A (en) 2011-08-31
IL178672A0 (en) 2007-02-11
DE502005002927D1 (de) 2008-04-03
SI1740569T1 (sl) 2008-06-30
NZ550757A (en) 2010-06-25
AR053302A1 (es) 2007-05-02
AU2005238144B2 (en) 2010-08-26
RS50553B (sr) 2010-05-07
RU2375356C2 (ru) 2009-12-10
UA87306C2 (en) 2009-07-10
ES2299026T3 (es) 2008-05-16
CA2563401C (en) 2012-08-07
PT1740569E (pt) 2008-03-31
CR8650A (es) 2007-12-04
HK1101823A1 (zh) 2007-10-26
CA2563401A1 (en) 2005-11-10
ECSP066941A (es) 2006-12-20
EP1864979A1 (de) 2007-12-12
EP1740569B1 (de) 2008-02-20
ZA200607668B (en) 2008-03-26
MY140903A (en) 2010-01-29
TWI359016B (en) 2012-03-01
ATE386737T1 (de) 2008-03-15
DE102004020186A1 (de) 2005-11-17
KR20070007346A (ko) 2007-01-15
UY28868A1 (es) 2005-11-30
WO2005105781A1 (de) 2005-11-10
AU2005238144A1 (en) 2005-11-10
JP4939401B2 (ja) 2012-05-23
EP1864979B1 (de) 2011-09-07
PE20060172A1 (es) 2006-03-31
EP1740569A1 (de) 2007-01-10

Similar Documents

Publication Publication Date Title
CN100572376C (zh) 用作tafia抑制剂的咪唑衍生物
KR102603729B1 (ko) Jak 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리딘 화합물 및 이의 용도
CN101213187B (zh) 作为rho-激酶抑制剂的异喹啉衍生物
EP3538526B1 (en) Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors
JP4769082B2 (ja) ウレア誘導体、その製造法及び用途
TWI228123B (en) Antithrombotic compounds
JP2021519766A (ja) ＸＩＩａ因子インヒビター
JP2000508334A (ja) ピラジノン系トロンビン阻害薬
JP2000512652A (ja) 腫瘍の治療または免疫抑制におけるピリジルアルカン、ピリジルアルケンおよび／またはピリジルアルキン酸アミド類の用途
AU2016270903A1 (en) 4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists for use in the treatment of cardiovascular disorders
FR2911138A1 (fr) Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
WO2013049591A2 (en) Dual inhibitor compounds and methods of use thereof
CN101516834A (zh) 用作凝血因子IXa抑制剂的异丝氨酸衍生物
KR20230157981A (ko) 인자 xiia 저해제
EP1189899B1 (en) Pyrazinone thrombin inhibitors
EP2970141A2 (en) Halogenopyrazoles as inhibitors of thrombin
JP2011510026A (ja) アザビシクロオクタンの誘導体、その製造方法及びそのジペプチジルペプチダーゼｉｖの阻害剤としての用途
CN101516833B (zh) 用作凝血因子IXa抑制剂的酒石酸衍生物
WO2002074743A1 (en) Aryl-substituted alicyclic compound and medical composition comprising the same
EP1937673A1 (de) Imidazolderivate als inhibitoren von tafi-a
US6462050B1 (en) Thrombin inhibitors
US6521625B2 (en) Pyrazinone thrombin inhibitors
JP5045442B2 (ja) ベンゼン誘導体又はその塩
JP2004520399A (ja) トロンビン阻害剤
TWI919549B (zh) 抑制ｔｎａｐ的化合物及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1101823

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1101823

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20091223

Termination date: 20180407